What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Nagao S, Nishio S, Okada S, Otsuki T, Fujiwara K, Tanabe H, Takano M, Hasumi Y, Takei Y, Hasegawa T, Matsumoto T, Fujiwara K, Takekuma M, Nakamura K, Shimada M, Suzuki M, Kigawa J.
Nagao S, et al. Among authors: takekuma m.
Cancer Chemother Pharmacol. 2015 Aug;76(2):335-42. doi: 10.1007/s00280-015-2793-9. Epub 2015 Jun 20.
Cancer Chemother Pharmacol. 2015.
PMID: 26092322